Commentaries
Vol. 4 No. 2 (2025)
Comments on “Safe and effective anticoagulation use: case studies in anticoagulation stewardship”
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 1 July 2025
1324
Views
419
Downloads
Authors
Quoting Jake Elwood, after reading the review by May et al., “we’ve seen the light.” Indeed, the term “anticoagulation stewardship” can serve as a programmatic manifesto for every scientific society dealing with hemostasis and thrombosis. The expression “antimicrobial stewardship” has become widely used and integrated into healthcare service planning, so why not start thinking in terms of “anticoagulation stewardship”?.....
Downloads
Download data is not yet available.
Citations
1. May JE, Allen AL, Samuelson Bannow BT, et al. Safe and effective anticoagulation use: case studies in anticoagulation stewardship. J Thromb Haemost 2025;23:779-89. DOI: https://doi.org/10.1016/j.jtha.2024.11.024
2. Budnitz DS, Shehab N, Lovegrove MC, et al. US emergency department visits attributed to medication harms, 2017-2019. JAMA 2021;326:1299-309. DOI: https://doi.org/10.1001/jama.2021.13844
3. Burnett AE, Barnes GD. A call to action for anticoagulation stewardship. Res Pract Thromb Haemost 2022;6:e12757. DOI: https://doi.org/10.1002/rth2.12757
4. Anticoagulation Forum. Core Elements of Anticoagulation Stewardship Programs. Newton, Anticoagulation Forum; 2019.
5. National Quality Forum. Advancing Anticoagulation Stewardship: A Playbook. Washington, DC, National Quality Forum; 2022.
6. Barnes GD, Nallamothu BK, Sales AE, Froehlich JB. Reimagining anticoagulation clinics in the era of direct oral anticoagulants. Circ Cardiovasc Qual Outcomes 2016;9:182–5. DOI: https://doi.org/10.1161/CIRCOUTCOMES.115.002366
7. Sylvester KW, Chen A, Lewin A, et al. Optimization of DOAC management services in a centralized anticoagulation clinic. Res Pract Thromb Haemost 2022;6:e12696. DOI: https://doi.org/10.1002/rth2.12696
8. Samuelson Bannow B. Are outpatient anticoagulation management services the wave of the future (again)? Res Pract Thromb Haemost 2022;6:e12735. DOI: https://doi.org/10.1002/rth2.12735
9. Lee J, Lindsley J, Chasler J, et al. The impact of an antithrombotic stewardship program on heparin-induced thrombocytopenia management. J Pharm Pract 2023;36:1343-9. DOI: https://doi.org/10.1177/08971900221116185
10. Rudd K, Winans A, Triller D. Standardizing periprocedural anticoagulation management: a stewardship initiative. J Thromb Thrombolysis 2023;56:361-7. DOI: https://doi.org/10.1007/s11239-023-02854-2
11. Samuelson Bannow BT. Management of abnormal uterine bleeding on anticoagulation: the patient-clinician perspective. J Thromb Haemost 2024;22:1819-25. DOI: https://doi.org/10.1016/j.jtha.2024.04.002
12. National Institute for Health and Care Excellence (NICE). Heavy menstrual bleeding: assessment and management. National Institute for Health and Care Excellence: Clinical Guidelines. London, NICE; 2021.
13. Silvari V, Crowley E, Carey M, et al. Value of hospital anticoagulation stewardship programme: a systematic review. Thromb Update 2024;14:100158. DOI: https://doi.org/10.1016/j.tru.2023.100158
14. McLintock C, Pabinger I, Bauer KA, et al. International Society on Thrombosis and Haemostasis core curriculum project: core competencies in clinical thrombosis and hemostasis. J Thromb Haemost 2016;14:3-27. DOI: https://doi.org/10.1111/jth.13162
How to Cite
1.
Marietta M, Castaman G. Comments on “Safe and effective anticoagulation use: case studies in anticoagulation stewardship”. Bleeding Thromb Vascul Biol [Internet]. 2025 Jul. 1 [cited 2025 Nov. 9];4(2). Available from: https://www.btvb.org/btvb/article/view/180
Copyright (c) 2025 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Share
Similar Articles
- CO06 | Recurrences of catheter associated upper extremity deep vein thrombosis in cancer: a two year prospective study with enoxaparin , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO50 | Treatment with BTK inhibitors in patients affected by chronic lymphocytic leukemia: safety and hemostasis , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Maria J. Fernandez Turizo, Rushad Patell, Jeffrey I. Zwicker, Identifying novel biomarkers using proteomics to predict cancer-associated thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Kartik Akkihal, Thomas Varkey, James Kelbert, The use of creatine and the development of deep vein thrombosis. A scoping review , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 3 (2024)
- CS01 | Elucidating the evil relationship of metabolic dysfunction–associated fatty liver disease with cardiovascular comorbidities: the complex interplay among hypercoagulability, inflammation and liver fibrosis , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Silvia Cardi, Filippo Catalani, Luca Valerio, Stefano Barco, From rare to aware: confronting Lemierre syndrome , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 3 (2024)
- Niccolò Bitto, Vincenzo La Mura, Anna Ludovica Fracanzani, Armando Tripodi, Is non-alcoholic fatty liver disease a prothrombotic risk factor? , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- Mehrie H. Patel, Alok A. Khorana, New drugs, old problems: immune checkpoint inhibitors and cancer-associated thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Gaetano Torlone, The metaphor of Ukrainian science "bleeding" , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
You may also start an advanced similarity search for this article.
Most read articles by the same author(s)
- Giovanni Di Minno, Gaia Spadarella, Ilenia Lorenza Calcaterra, Giancarlo Castaman, Paolo Simioni, Raimondo De Cristofaro, Cristina Santoro, Flora Peyvandi, Matteo Di Minno, The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Giancarlo Castaman, Gene transfer in hemophilia B: a big step forward , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- Gianfranco De Girolamo, Luca Sarti, Sonia Cecoli, Karin Bonora, Chiara Ajolfi, Francesco Bellelli, Valeria Coluccio, Gualtiero Palareti, Marco Marietta, Safety and efficacy of treatment with vitamin K antagonists in patients managed in a network of anticoagulation services or as routine general care , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Lisa Pieri, Silvia Linari, Francesca Salvianti, Monica Attanasio, Giancarlo Castaman, Impaired platelet function in Hermansky-Pudlak syndrome associated with novel mutations in HPS3, HPS6 and HPS8 genes , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 3 (2024)
